XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Interim Consolidated Statements of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 187 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2012
Revenue $ 0 $ 0 $ 0
Operating expenses:      
Research and development 296 315 67,389
Gain on deferred lease inducements 0 0 (497)
Impairment of capital assets 0 0 386
Acquired in-process research and development 0 0 13,094
General and administrative 320 706 30,869
Loss from operations (616) (1,021) (111,241)
Other income (expense):      
Settlement of Cadherin Biomedical Inc. litigation 0 0 (1,283)
Interest expense 0 0 (19)
Unrealized/realized gain on derivatives 3,327 5,680 8,147
Other income / (expense) (4) 0 260
Interest income and other 8 10 2,880
Total other income, net 3,331 5,690 9,985
Net income / (loss) and comprehensive income / (loss) $ 2,715 $ 4,669 $ (101,256)
Earnings per share of common stock, basic $ 0.11 $ 0.23  
Earnings per share of common stock, diluted $ 0.11 $ 0.19  
Weighted-average number of common shares outstanding, basic 25,158 20,565  
Weighted-average number of common shares outstanding, diluted 25,158 25,001